601567 三星医疗
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入6,997,46626.11%11,462,5089,098,2037,022,9027,092,709
减:营业总成本5,848,53525.17%9,763,0058,045,1076,520,1786,279,015
    其中:营业成本4,575,56419.72%7,566,2576,470,4775,241,3575,054,566
               财务费用54,080-190.53%(8,838)(14,853)88,30294,541
               资产减值损失(14,589)-5,581.78%(12,987)(11,539)(13,066)(15,861)
公允价值变动收益(49,958)12,542.60%116,975(107,481)103,69765,383
投资收益128,5747.79%296,13784,951204,334337,618
    其中:对联营企业和合营企业的投资收益103,05515.03%230,272189,892134,226118,764
营业利润1,315,50327.65%2,270,4521,152,349851,2271,192,528
利润总额1,358,64432.28%2,262,0671,152,047846,8131,188,533
减:所得税费用204,54732.81%341,263187,042139,204227,654
净利润1,154,09732.19%1,920,804965,005707,609960,879
减:非控股权益4,08821.88%17,10216,88917,5674,759
股东净利润1,150,00932.23%1,903,702948,116690,043956,120

市场价值指针
每股收益 (元) *0.81030.65%1.3500.6700.5000.690
每股派息 (元) *----0.6500.3500.3200.350
每股净资产 (元) *7.87111.35%7.7946.7296.3336.217
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容